Response to Dr. Okumura

Affiliations

¹ Department of Mental Health Policy and Evaluation, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan; National Hospital Organization, Tottori Medical Center, Tottori, Japan; School of International Politics, Economics and Communication, Aoyama Gakuin University, Tokyo, Japan; Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Funabashi, Japan; Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Japan; Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan.

Comment

Yoshio Yamanouchi et al. Int J Neuropsychopharmacol. 2017.

. 2017 Jul 1;20(7):548-549.

doi: 10.1093/ijnp/pyx020.

¹ Department of Mental Health Policy and Evaluation, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan; National Hospital Organization, Tottori Medical Center, Tottori, Japan; School of International Politics, Economics and Communication, Aoyama Gakuin University, Tokyo, Japan; Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Funabashi, Japan; Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Japan; Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan.

No abstract available

Comment on

Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method.
Yamanouchi Y, Sukegawa T, Inagaki A, Inada T, Yoshio T, Yoshimura R, Iwata N. Yamanouchi Y, et al. Int J Neuropsychopharmacol. 2014 Dec 11;18(5):pyu016. doi: 10.1093/ijnp/pyu016. Int J Neuropsychopharmacol. 2014. PMID: 25522380 Free PMC article. Clinical Trial.
Use of a Spin Strategy Can Result in Unreliable Research Findings.
Okumura Y. Okumura Y. Int J Neuropsychopharmacol. 2017 Jul 1;20(7):546-547. doi: 10.1093/ijnp/pyx013. Int J Neuropsychopharmacol. 2017. PMID: 28199677 Free PMC article. No abstract available.

1. Okumura Y. (2017) Use of a spin strategy can result in unreliable research findings. Int J Neuropsychopharmacol Feb 11. doi:10.1093/ijnp/pyx013. [Epub ahead of print] - PMC - PubMed
1. Yamanouchi Y, Sukegawa T, Inagaki A, Inada T, Yoshio T, Yoshimura R, Iwata N. (2015) Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method. Int J Neuropsychopharmacol 18:1–8. - PMC - PubMed
1. Iwata N. (2011) The clinical study to correct multiple and large amount of administering to antipsychotic safety and effectively (in Japanese) http://mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resarchNum=201027094A.
1. Sukegawa T, Yamanouchi Y, Inagaki A, Inada T, Yoshio T, Yoshimura R, Iwata N. (2014) Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan. BMC Psychiatry 14:103. - PMC - PubMed